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Tumor Cell Repopulation between Cycles of
Chemotherapy is Inhibited by Regulatory T-Cell Depletion
in a Murine Mesothelioma Model
Licun Wu, MD, Zhihong Yun, MSc, Tetsuzo Tagawa, MD, PhD, Katrina Rey-McIntyre, BSc,
Masaki Anraku, MD, MSc, and Marc de Perrot, MD, MSc
Introduction: Malignant pleural mesothelioma is a highly aggressive
cancer with poor prognosis. We have previously demonstrated that
regulatory T cells (Treg) depletion can impact tumor microenvironment
when combined with chemotherapy. The aim of this study is to analyze
the impact of Treg depletion on tumor cell repopulation during cycles
of chemotherapy in a murine mesothelioma model.
Methods: Tumor-bearing mice were treated with chemotherapy
once weekly to mimic clinical settings and with PC61 to cause Treg
depletion after each cycle of chemotherapy. Tumor cell repopulation
was evaluated by BrdU labeling index with immunohistochemistry
and flow cytometry, and Ki67 gene expression was determined by
real-time reverse-transcribed polymerase chain reaction. The pro-
portion of CD4 CD25Foxp3 Tregs, CD4, and CD8 T cells
in the tumor, spleen, draining lymph node, and peripheral blood
from tumor-bearing mice was determined by using flow cytometry,
and gene expression of activated T-cell-related cytokines was quan-
tified by enzyme-linked immunosorbent assay and reverse-tran-
scribed polymerase chain reaction.
Results: Tumor growth delay was achieved by cisplatin followed by
PC61 or cyclophosphamide. The BrdU labeling index indicated that
tumor cell repopulation between cycles of cisplatin was significantly
inhibited by PC61. The CD4CD25Foxp3 Tregs in tumor and
lymphoid organs were almost completely depleted, whereas the
CD4 or CD8 T cells did not change. PC61 after chemotherapy
resulted in an increase of gene expression of interferon-, granzyme
B, perforin, and IP-10, thus leading to tumor cell lysis in cytotoxic
lymphocyte assay. Nevertheless, cell killing induced by cyclophos-
phamide combined with cisplatin was due to cytotoxicity rather than
specific immune response.
Conclusion: Treg depletion between cycles of chemotherapy could
improve the outcome of mesothelioma. Nevertheless, this effect
seems limited, and more effective approaches need to be developed.
Key Words: Mesothelioma, Chemotherapy, Repopulation, Regula-
tory T cells (Treg), Immunotherapy.
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The incidence of malignant pleural mesothelioma (MPM)has increased by 65% over the past 2 decades, and the
peak incidence is predicted to occur in 10 to 20 years.1–3
MPM is a highly aggressive neoplasm with poor prognosis.
Surgery, chemotherapy, and radiotherapy alone or in combi-
nation have not been successful in the treatment of MPM, and
the overall prognosis remains poor with a median survival of
only 8 to 12 months after diagnosis.4–6 Combined modality
approaches with induction chemotherapy followed by surgery
with an extrapleural pneumonectomy and high-dose hemitho-
racic radiotherapy is an aggressive treatment associated with
some benefit in a limited number of patients.6 Currently,
pemetrexed (Alimta) combined with cisplatin is the first-line
chemotherapy for MPM as a large randomized phase III trial
demonstrated a significant survival advantage, when com-
pared with cisplatin alone.7–10
One area in cancer research that has recently been
highlighted is the importance of repopulation of surviving
tumor cells between courses of chemotherapy and radiation
therapy.11–15 The rate of repopulation of surviving cells has
been reported to increases during fractionated radiotherapy
and between cycles of chemotherapy limiting the ability to
control tumors.12,13 Repopulation is likely to be more impor-
tant with chemotherapy than with radiation therapy because
of the longer intervals between cycles of treatment and is a
potential cause of clinical resistance to chemotherapy.11 Mod-
eling has shown that accelerating repopulation after sequen-
tial courses of chemotherapy could lead to regrowth of
tumors after initial shrinkage without any change in the
intrinsic sensitivity of the cells to the drugs used.11 Thus,
accelerating repopulation might be an important cause of
clinical drug resistance. Inhibitors such as the antiestrogenic
arzoxifene14 and an inhibitor of the mammalian target of
rapamycin CCI-779 have been used during the intervals
between chemotherapy in estrogen-sensitive breast and in
prostate cancer xenografts, respectively, to limit the risk of
repopulation between chemotherapy cycles.15
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Regulatory T cells (Treg) are present in most solid
tumors including mesothelioma.16–19 Antitumor immunity is
largely dependent on a balance between suppressive Tregs
and effector CD4 and CD8 T cells. The suppression of an
antitumor immune response by Treg has been well charac-
terized.20 Treg cells suppress the function of effector T
cells through cell-contact-dependent mechanisms or/and
the production of the immunosuppressive cytokines. Inter-
leukin (IL)-10 and transforming growth factor- are re-
leased by Treg cells and account for the immunosuppres-
sion in the tumor microenvironment. In our previous study,
concurrent administration of chemotherapy and Treg de-
pletion was able to prolong survival of mesothelioma-
bearing mice in an intrapleural model possibly by modi-
fying the tumor environment.21
In this study, we have analyzed the effect of Treg
depletion on tumor cell repopulation by depleting Treg cells
between the intervals of chemotherapy in a murine mesothe-
lioma model. PC61 is an antimouse monoclonal antibody
against CD25, which mainly expresses on Treg cells.19,21 A
low dose of cyclophosphamide was used as a positive control
as it has been shown to deplete Treg cells in mice and patients
with cancer.22–24 To the best of our knowledge, the impact of
immunotherapy on the repopulation of cancer cells in be-
tween cycles of chemotherapy has never been studied.
MATERIALS AND METHODS
Tumor Cell Line and Mice
Murine mesothelioma AC29 cells, kindly provided in
2006 by Dr. Jay Kolls from University of Pittsburgh, were
maintained in RPMI1640 medium supplemented with
2 mmol/L L-glutamine (Invitrogen, Carlsbad, CA). Cells
were confirmed to be mycoplasma free. Medium contained
10% fetal bovine serum, 1% penicillin, and streptomycin.
The AC29 tumor was developed in asbestos-exposed mice
by Davis et al.25 and has similar histology to human
mesothelioma.
Female Crossing Bagg Albino (CBA) syngeneic mice at
6 to 8 weeks of age were purchased from Jackson Laboratories
(Bar Harbor, ME) and acclimatized in the animal colony for a
week before experimentation. The animals were housed in
microisolator cages, 5/cage, in a 12-hour light/dark cycle. Sterile
water and rodent food were given ad libitum. Animal care and
experiments were performed in accordance with institutional
and Canadian Institute of Health guidelines. This study was
approved by the institutional research ethics board (REB).
Tumor Cell Injection and Treatment
AC29 cells (2 106) were injected subcutaneously into
the right flank of female CBA mice. Treatment was initiated
when tumors grew to a size of 5 mm in diameter at 4 1 days
after tumor cell injection. Subcutaneous mesothelioma model
made it possible to directly evaluate the antitumor effect by
measuring tumor size, and also tumor cell repopulation be-
tween cycles of treatments can be quantitatively evaluated.
Tumor-bearing mice were randomly divided into groups as
follows: (1) no treatment (NoRx); (2) Treg depletion alone,
antimouse CD25 monoclonal antibody PC61 (eBioscience,
San Diego, CA) 100 g/mouse was injected intraperitoneally
(IP) once weekly for three doses on days 1, 8, and 15; (3)
chemotherapy alone, cisplatin (Cis, Mayne Pharma Inc.,
Montreal, QC) 5 mg/kg body weight was injected intrave-
nously (IV) through the tail vein, once weekly for 3 weeks on
days 0, 7, and 14 (The first day of treatment was referred to
as day 0); (4) cyclophosphamide (CY, Sigma, St. Louis, MO)
alone: 100 mg/kg body weight was injected IP once weekly
for three doses on days 1, 8, and 15; (5) combination of
chemotherapy and Treg depletion (CisPC61, CPC): cispla-
tin 5 mg/kg body weight was injected, IV, once weekly for 3
weeks, and PC61 100 g/mouse was injected IP, 1 day after
each cycle of chemotherapy, i.e., days 1, 8, and 15; and (6)
combination of cisplatin and cyclophosphamide (CCY): cis-
platin 5 mg/kg body weight was injected, IV, once weekly for
3 weeks, and low dose of cyclophosphamide (CY) 100 mg/kg
was given IP after each dose of cisplatin. The treatment
schema is shown in Figure 1A. Tumor size was measured
twice weekly by a caliper, and tumor volume was esti-
mated by a formula: V  ab2/6, whereas a and b
represent the longest and shortest maximal perpendicular
diameters, respectively.
Cell Preparation and Staining of T-Cell
Population by Flow Cytometry
T-cell subsets were determined by using flow cytom-
etry. At different time points after treatment, spleens and
draining lymph nodes were removed from tumor-bearing
mice and placed into ice-cold RPMI1640 medium containing
1% fetal bovine serum. The auxiliary lymph nodes from the
tumor side were called draining lymph nodes. Peripheral
blood was drawn from the hearts of mice that were immedi-
ately euthanized by inhalation of carbon dioxide. Homoge-
nized spleen and lymph node were passed through the Cell
Strainer ([Phi]40 m, BD Biosciences, San Diego, CA) to
achieve single cells. ACK lysis buffer (Invitrogen, Carlsbad,
CA) was added and allowed to react for at least 15 minutes at
room temperature (RT) to lyse red blood cells. After washing
thrice with staining buffer, appropriate dilutions (1:50100)
of Abs or isotype controls were added to each tube, 15
minutes at RT in the dark. Staining of surface markers
including CD3, CD4, CD8, and CD25 were washed thrice
with staining buffer and resuspended in 1% paraformalde-
hyde/phosphate-buffered saline (PBS) (vol/vol) (Sigma). Af-
ter fixation with 1% paraformaldehyde at 4°C overnight, cells
were permeabilized for FoxP3 intracellular staining and fixed
with 200 l Permeabilization/Fixation Solution (eBioscience)
and then washed with permeabilization buffer twice. Anti-
mouse Foxp3 antibody (1:30) was added and maintained at
RT for 20 minutes.
Single cell suspensions were stained with monoclonal
antibodies conjugated with different fluorescent dyes, CD3
(clone: 17A2)-FITC, CD4 (clone: RM4-5)- PerCP, CD8
(clone: H35-17.2)-APC, CD25 (IL2R, p55)-APC, and
FoxP3 (FJK-16s)-PE. All antibodies and isotypes were pur-
chased from BioLegend (San Diego, CA) and eBioscience.
Flow cytometry analysis was performed on a FACS Calibur
(Becton Dickinson, Mountain View, CA) using Cell Quest
and FlowJo softwares.
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Tumor Cell Repopulation was Evaluated by
Immunostaining and Flow Cytometry for BrdU
Incorporation and Quantitative Reverse-
Transcribed Polymerase Chain Reaction for
Ki67 Gene Expression
Animals were killed approximately 3 hours after bro-
modeoxyuridine (BrdU, Roche, Mannheim, Germany) 100
mg/kg body weight was injected IP. Tumor tissues were
removed at different time points after treatment and snap
frozen immediately in liquid nitrogen and then transferred to
dry ice and kept at 80°C until frozen sectioning was
performed. Frozen sections were fixed in cold ethanol. En-
dogenous peroxidases, avidin, and biotin were blocked using
1% hydrogen peroxide and the Avidin/Biotin blocking kit
(Dako, Carpinteria, CA). Sections were stained with a pri-
mary monoclonal antibody (1:50) against BrdU (eBioscience)
and secondary antibody linked to streptavidin-HRP (Dako).
After washing, one Sigma FAST (D-4168) DAB (3, 3-di-
aminobenzidine) tablet and one urea hydrogen tablet (Sigma)
were added to ddH2O to serve as a peroxidase substrate (125
l/section), and slides were counter stained with hematoxylin
to visualize nuclear staining. Sections were then dehydrated
and mounted with DPX (Ultramount, Scot Scientific).
Immunostaining in sections was quantified by using
Aperio ImageScope digital scanner and ImageScope Viewer
software version 9.0 (Vista, CA) under 200 magnification.
Tumor cell repopulation was quantified as the proportion of
BrdU positive nuclear areas divided by total nuclear areas.13
Single tumor cells were prepared by passing through
the cell strainer and stained similarly as for intracellular
FoxP3 staining. DNase I (Sigma) was applied after permea-
bilization. BrdU-FITC antibody 1:30 was added, and cells
were exposed at RT in the dark for 30 minutes, then washed
thrice for flow cytometry.
Gene expression of Ki67 was determined by reverse-
transcribed polymerase chain reaction (RT-PCR) (described
later).
In Vitro Generation of Tumor-Specific
Cytotoxic Lymphocytes by Chromium-Release
Assay
Splenocytes derived from mice after treatment were
pooled into 24-well plates at a concentration of 2.5 to 5 
106/ml. After 3 days of culture, half of the medium was
replaced with fresh medium containing IL-2 (final concentra-
tion of 10 U/ml). On day 5, cells were harvested and tested in
a standard 4-hour 51Cr release assay.26 Briefly, target AC29
cells (106 in 100 l of PBS) were labeled with 100 Ci/ml
of Cr51 solution for 1 hour and incubated with effector cells
for 4 hours at different effector to target (E:T) ratios in
triplicate, and 51Cr release was determined by analyzing the
supernatants in a Microplate Scintillation Counter (Perkin
Elmer, Waltham, MA). The percentage of specific lysis was
calculated according to the formula: 100  ([experimental
release  spontaneous release]/[maximal release  sponta-
neous release]). Spontaneous release and maximum release
were obtained from wells containing target cells incubated in
medium alone or in 2% acetic acid, respectively.
Cytokine Production Determined by Enzyme-
Linked Immunosorbent Assay
Measurement of cytokines such as interferon (IFN)- and
granzyme B in both the peripheral blood and tumor tissues was
carried out using enzyme-linked immunosorbent assay (ELISA).
Serum was prepared from whole blood of mice at 7 days after
completing treatments. Simultaneously, tumor tissues were ho-
mogenized mechanically in PBS, and the supernatant was used
for ELISA. Data presented are expressed as picogram of cyto-
kine per 100 mg of tumor tissues.
FIGURE 1. Murine mesothelioma
AC29 cells were injected subcuta-
neously (SC) into the flanks of CBA
mice. Once tumors are palpable
(approximately 5 mm in diameter
at day 4  1 posttumor cell injec-
tion), treatment was initiated as
follows: no treatment, cisplatin
(Cis) alone, cyclophosphamide
alone, PC61 alone, cisplatin com-
bined with Treg depletion by
CD25 monoclonal antibody PC61
(CPC), or cisplatin combined with
low dose of cyclophosphamide
(CCY) (A). Tumor growth delay
after both combination treatments
with PC61 or CY following cisplatin
was achieved (B and C). Each
group contained at least five mice.
Tumor growth curves after treat-
ment shown are the averages of
three experiments. *p  0.05,
compared with controls.
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All procedures were performed according to the proto-
cols provided by the manufacturer (eBioscience). Plates were
read at 450 nm using the Dynex Opsys MR plate reader
(Thermo Fisher Labsystems, Pittsburgh, PA).
Gene Expression Determined by Real-Time RT-PCR
Total RNA was extracted from tumor tissues using
TRizol Reagent (Invitrogen), and RNeasy MinElute Cleanup
kit (QIAGEN, Valencia, CA) enabled cleanup of RNA.
Complementary DNA (cDNA) was synthesized with High-
Capacity cDNA Reverse Transcription kits (ABI, Foster City,
CA) on a PTC-100 Programmable Thermal controller (MJ
research Inc., Ramsey, MN) following the manufacturer’s
protocols. Regular PCR was carried out to establish RT-PCR
standards of all target genes including IFN-, granzyme B,
perforin, IP-10, and Ki67 and house-keeping gene glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH). DNA frag-
ments were obtained from regular PCR on a PTC-100 Pro-
grammable Thermal. Regular PCR was performed by 10
High Fidelity PCR Buffer, Platinum Taq polymerase High
Fidelity, 50 mM MgSO4, 10 mM dNTP Mix (Invitrogen). A
SYBR GREEN real-time PCR was performed on ABI
PRISM 7900HT system. PCR was composed of Power
SYBR GREEN PCR 2 Master Mix (ABI), 200 nM primer,
and 2 l 500 ng/l cDNA  40 cycles. Primers of all target
genes and house-keeping gene were designed by ABI Prism
Primer Express Version 2.0 and presented in Table 1.
Statistical Analysis
All data are presented as the mean  standard error of
the mean (SEM). Statistical analysis was conducted by un-
paired Student’s t test. p values less than 0.05 were consid-
ered as significantly different for all comparisons. p less than
0.05 was represented by an asterisk.
RESULTS
Synergistic Effect of Chemotherapy and Treg
Cell Depletion on Tumor Growth
Tumor growth curves indicated that cisplatin combined
with Treg blockade resulted in the best tumor growth delay in
AC29 tumor model, whereas cisplatin alone, cyclophosph-
amide alone, and PC61 alone all had small effects to delay the
growth of AC29 tumors. Administration of anti-CD25 mono-
clonal antibody (PC61) during the intervals of cisplatin che-
motherapy (CPC) was significantly more effective than com-
bination of CCY (Figures 1B, C). The body weight of mice
did not change significantly after completing treatment.
Inhibition of Tumor Cell Repopulation by
Administration of PC61 during Courses of
Chemotherapy
The percentage of positive nuclear staining for BrdU in
tumor cells was lower during combination chemotherapy
with CPC and CCY than with cisplatin alone (Figure 2A).
The BrdU labeling index of tumor cells was also significantly
lower in the tumors treated with cisplatin and PC61 than in
those treated by cisplatin alone or in untreated tumors. Rep-
resentative images and their quantification of BrdU immuno-
staining are shown in Figures 2B, C.
RT-PCR data showed that the gene expression of pro-
liferation marker Ki67 in tumors treated with CPC and CCY
had lowest levels, which are consistent with BrdU staining in
immunohistochemistry and flow cytometry, but cisplatin
alone only displayed minimal change (Figure 2D).
The Impact of Treg Cell Depletion on Total
CD4and CD8 T-Cell Proportion in Lymphoid
Organs during Chemotherapy
Single cells from the spleen, draining lymph node, and
peripheral blood were stained after completing weekly treat-
ments (day 21 after tumor cell injection). The anti-CD25
monoclonal antibody PC61 could deplete Treg cells dramat-
ically during the intervals between chemotherapy, and the
effect lasted for at least a week. The proportion of Treg cells
was significantly lower than that of any other group, although
low-dose cyclophosphamide (used as a positive control in
depleting Tregs) was also able to induce a decrease in
proportion of Treg cells, but the effect was mild, when
compared with PC61. Cisplatin alone was not able to deplete
Treg cells (Figure 3A). Cisplatin alone, CPC, and CCY did
not impact on the overall population of either CD4 or CD8
T cells in blood, draining lymph node, or spleen (Figure 3B).
The Impact of Treg Cell Depletion on Total
CD4and CD8 T-Cell Proportion in Tumor
during Chemotherapy
The percentage of intratumoral Tregs determined by
CD4CD25FoxP3 cells was 10.9  0.9 in untreated mice
and 8.9  2.6 in mice that received cisplatin alone. Combi-
nation therapy with CPC resulted in a dramatic decrease of
Tregs in the tumor (p  0.05 for each comparison, Figure
4A). Nevertheless, the total percentage of CD4 and CD8 T
cells did not change significantly in the tumor except for
CD8 T cells in the CCY-treated group, which dramatically
decreased (Figure 4B).
TABLE 1. Primers of Target Genes and House-Keeping
Gene Used for RT-PCR
Oligo Name Oligo Sequence (5–3)
GAPDH-F GGTGAAGGTCGGTGTGAACG
GAPDH-R AATCTCCACTTTGCCACTGCA
IFN--F CAGCAAGGCGAAAAAGGATG
IFN--R AGCTCATTGAATGCTTGGCG
Granzyme B-F TCTCTGGCCTCCAGGACAAA
Granzyme B-R AAGGCCATGTAGGGTCGAGAGT
Perforin-F AGCCAATTTTGCAGCTGAGAAG
Perforin-F GCTCTGAGCGCCTTTTTGAA
IP-10-F TGCTGGGTCTGAGTGGGACT
IP-10-R CTGGCCCGTCATCGATATG
Ki67-F CTCAGCTCCTGCCTGTTTGG
Ki67-R GGCAGCTGGATACGAATGTCA
IFN, interferon; RT-PCR, reverse-transcribed polymerase chain reaction.
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Tumor-Specific Cell Killing by Cytotoxic
Lymphocytes Assay
We checked whether splenocytes from tumor-bearing
mice were functional by in vitro cytotoxic lymphocytes
(CTLs) assay. The effectors were used to kill target cells in a
standard 51Cr release. When the E/T ratio was 90:1, the cell
killing of AC29 was found to be approximately 40%. All
tumor-bearing groups had specific cell killing except CCY-
treated mice, probably because CCY treatment resulted in
major lymphocyte and CD8 T-cell depletion. As expected,
splenocytes from naive mice did not kill AC29 cells as they
have never encountered tumor-associated antigens (Figure 5).
The Effect of PC61 After Chemotherapy on
Gene Expression of Cytokines
Cytokines including interferon (IFN)-, granzyme B,
perforin, and IP-10, which are known to modulate the im-
mune response, were detected by real-time RT-PCR. Genes
encoding these cytokines had higher levels of expression in
the tumors treated with PC61 combined with cisplatin than in
the other groups. In contrast, low-dose cyclophosphamide
combined with cisplatin did not induce increased expression
of these genes (Figure 6A). The ELISA assay also showed
that treatment with PC61 after cisplatin resulted in an in-
crease of IFN- and granzyme B production, whereas in the
tumors treated with cyclophosphamide combined with cispla-
tin, they were hardly detected (Figure 6B).
DISCUSSION
Our results demonstrated that tumor cell repopulation
between cycles of chemotherapy was inhibited by Treg de-
pletion with PC61. The CD4CD25Foxp3 Tregs in tumor
and lymphoid organs were almost completely depleted,
FIGURE 2. Tumor cell repopulation between cycles of chemotherapy was inhibited by Treg cell depletion with anti-CD25
monoclonal antibody PC61. Single tumor cells were prepared at day 21 after treatment. BrdU was injected intraperitoneally
(IP) 3 hours before animals were killed. BrdU labeling index of tumor cells was determined by flow cytometry. Representative
data generated from five tumors of each group on day 21 showing tumor cell repopulation (A). Nuclear immunostaining of
BrdU incorporation and quantification of highlighted positive nuclear areas were shown in (B) and (C), respectively. Gene ex-
pression of internal proliferation marker Ki67 was evaluated by real-time reverse-transcribed polymerase chain reaction (RT-
PCR) (D). Columns, mean; bars, SEM. *p  0.05, compared with controls.
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whereas total CD4 or CD8 T cells did not change signif-
icantly. PC61 after chemotherapy resulted in an increase of
gene expression of IFN-, granzyme B, perforin, and IP-10,
thus leading to specific tumor cell lysis in CTL assay. Nev-
ertheless, cell killing induced by cyclophosphamide com-
bined with cisplatin was due to cytotoxicity from the chemo-
therapy rather than specific immune response.
Tumor cell repopulation between cycles of chemother-
apy has been emphasized in cancer treatment as an important
cause of treatment failure.11,12 Strategies developed to inhibit
tumor cell repopulation have improved clinical outcomes,
and new strategies to overcome repopulation are currently
emerging.13–15 Our data suggested that Treg depletion with
PC61 has shown effective against tumor cell repopulation
during the intervals of chemotherapy. RT-PCR results indi-
cated that gene expression of cytokines such as IFN-,
granzyme B, and perforin had higher levels in the tumors
treated with chemotherapy followed by Treg depletion with
PC61 (CPC) than that in other groups. ELISA data and CTL
assay also showed that CPC-treated mice had higher level of
cytokine production and more specific cell lysis. Although
the combination chemotherapy (CCY) also resulted in tumor
growth delay, the gene expression of cytokines in tumor had
the lowest levels, when compared with other groups, and
CCY-treated mice had a lack of intratumoral cytokine pro-
duction or specific cell lysis, suggesting that tumor growth
delay was induced by cytotoxicity rather than specific anti-
tumor immune response.
High dose of cyclophosphamide (200 mg/kg) is an
alkylating chemotherapeutic agent with direct cytotoxicity
that decreased the number of all T-cell subsets, but low dose
(20–100 mg/kg body weight) has been known to deplete Treg
cells in mice.22,23,27 Low-dose cyclophosphamide signifi-
cantly inhibited tumor growth in immunocompetent but not
immunodeficient mice.27 In this study, low dose of cyclo-
phosphamide was used as control of PC61 administered
during chemotherapy; however, it induced significant deple-
tion of CD8 T cells in addition to Treg. Cyclophosphamide
(100 mg/kg) either alone or combined with cisplatin resulted
in a decrease of Treg number, but the effect is much weaker
than PC61.
The level of IFN- and granzyme B in peripheral blood
could not be detected by ELISA. Therefore, we also evalu-
ated the cytokines from tumor tissues to look at local pro-
duction in tumor site, as antitumor immune response usually
takes place inside the tumor. IFN- is produced predomi-
nantly by CD4 and CD8 cytotoxic T lymphocyte (CTL)
once antigen-specific immunity develops. Granzyme B is a
critical molecule for measuring tumor-specific T-cell re-
sponses.28 Activated T lymphocytes and splenocytes have
been shown to express IP-10, a chemoattractant for activated
T lymphocytes.29
It has been demonstrated that IFN- and granzyme B
are important for the ability of CD8 T and natural killer
(NK) cells to kill their targets.28 Nevertheless, Treg cells
derived from tumor environment could induce NK and CD8
T-cell death in a granzyme B and perforin-dependent manner.
Granzyme B and perforin are important for the ability of Treg
cells to suppress NK and/or CD8 T-cell-mediated antitumor
responses.30,31 In this study, Tregs were almost completely
FIGURE 3. Populations of T-cell
subsets 7 days after completing
three cycles of chemotherapy. Sin-
gle cells from the spleen, draining
lymph node, and peripheral blood
were prepared and stained accord-
ing to the methods mentioned ear-
lier in the text. Treg cells were iden-
tified by positive staining of
CD4CD25FoxP3. The propor-
tion of Treg cells was analyzed based
on positivity of the above three
markers, and all p values are less
than 0.05 in the CPC group (A). To-
tal CD4 T cells and CD8 T cells
were determined by the proportion
of CD3CD4 and CD3CD8 cells
by flow cytometry, and there was no
significant difference as shown in (B).
Each group had at least five mice,
and the experiment was repeated
twice. Columns, mean; bars, SEM.
*p  0.05, compared with controls.
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depleted by PC61 as shown in Figures 3A and 4A; therefore,
IFN- and granzyme B were considered to be generated
mainly by cytotoxic CD8 T cells rather than Treg cells.
One major limitation of this study is that antimouse
CD25 monoclonal antibody PC61 was able to deplete the
CD25-expressing cells including Treg, some activated CD8
T cells, and some NK cells, thus this blockade is thought less
specific to Treg cells. We found that both low dose (1
g/mouse) and high dose (100 g/mouse) of PC61 were
effective against tumor growth when administered between
cycles of chemotherapy (unpublished data). It seems that low
dose was a bit more effective probably because high dose also
depleted some activated CD8 T cells and NK cells. The
other limitation of this study is that only one chemotherapeu-
tic agent cisplatin was selected as standard chemotherapy,
because cisplatin has been administered for the treatment of
MPM for a few decades and has been demonstrated effective.
Although Alimta was approved to treat MPM, the uncertain
results against tumor have been noticed in our tumor model
(unpublished data) and others.32 Pemetrexed alone had min-
imal effect in our intrapleural model unless it was combined
with Treg depletion.21 In addition, the effect of pemetrexed
alone on survival disappeared in immunodeficient mice, sug-
gesting that, at least in mice models of mesothelioma, one of
the main effect of pemetrexed may be to change the tumor
microenvironment to improve the antitumoral efficiency of
cytotoxic T cells rather than having a direct killing effect on
tumor cells. In this series of experiments, we observed that
cisplatin alone had a more potent antitumor effect than
pemetrexed alone. Nevertheless, the combination of cisplatin
to Treg depletion still provided significant additional benefit,
suggesting that the activation of cytotoxic T cells may still
provide additional effect to the direct killing effect of cispla-
tin on tumor cells. We, therefore, believe that the addition of
pemetrexed to cisplatin may be even more efficient and
reenforce the effect of Treg depletion in the tumor microen-
vironment.
Even though chemotherapy and immunotherapy used
to be considered antagonistic, recent studies suggested that
chemotherapy-induced cell death may enhance antitumor
immune response through promoting antigen presentation.20
Our data suggested that Treg depletion during chemotherapy
could result in inhibition of tumor cell repopulation through
inducing gene expression of CTL-related molecules, but the
effect did not eradicate the tumor; therefore, more effective
approaches such as cytotoxic T-lymphocyte antigen-4 block-
ade,33 adoptive transfer of tumor-specific CD8 T cells, or
intratumoral dendritic cell vaccine need to be combined with
current treatment settings.
In summary, considerable evidence has supported the
notion that Tregs promote tolerance to tumors including
mesothelioma. Targeting Tregs, therefore, represents a prom-
ising approach to cancer immunotherapy. We report in this
study that Treg depletion by PC61 has shown marked benefit
FIGURE 4. Populations of T-cell subsets 7 days after com-
pleting three cycles of chemotherapy. Single cells from the
tumor tissues were prepared and stained according to the
methods. Treg cells were identified by positive staining of
CD4CD25, CD4FoxP3, and CD4CD25FoxP3. The
proportion of Treg cells was analyzed based on positivity of the
above three markers (A). Total CD4 T cells and CD8 T cells
were determined by the proportion of CD3CD4 and
CD3CD8 cells by flow cytometry (B). (Each group had at
least five mice, and the experiment was repeated twice). Col-
umns, mean; bars, SEM. *p  0.05, compared with controls.
FIGURE 5. Specific cell killing of splenocytes derived from
AC29 tumor-bearing mice treated with cisplatin (Cis) or
PC61 alone, combination of cisplatin with PC61 (CPC) or
cyclophosphamide (CCY), and naive mice were also included
as control. This experiment was repeated at least twice. *p 
0.05, compared with naive mice.
Wu et al. Journal of Thoracic Oncology • Volume 6, Number 9, September 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1584
in inhibiting tumor cell repopulation between the intervals of
treatment with cisplatin. Our results imply that targeting Treg
after chemotherapy may be most effective at inhibiting tumor
cell repopulation through increasing cytokine production of T
cells. Nonetheless, more selectively targeting tumor-specific
Tregs may have the potential to improve antitumor immunity
than global Treg depletion. Future studies will provide a
better understanding of the molecular and cellular events that
lead to the activation of tumor-associated Tregs, which could
potentially present novel therapeutic targets.
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